GSK brings a Ray of Hope for People with Eosinophilic Asthma
GSK's Depemokimab reduces asthma attacks, aiming for £3 billion in annual sales, a key focus in respiratory medicine.
The experimental drug of GSK can successfully reduce asthma attacks in a late-stage trial, as per the reports. The British drugmaker expects to make annual sales of up to 3 billion pounds by providing this drug to the world.
The drug “depemokimab, showed "significant and meaningful reductions" in asthma attacks for patients with eosinophilic asthma, said GSK.
People with Eosinophilic asthma have high levels of Eosinophilia, a type of white blood cell. GSK bought asthma drug maker Aiolos Bio earlier this year for $1.4 Billion. Depemokimab is one of the 12 significant launches by GSK to start gearing up in 2025. GSK said this drug could be one of the first-approved ultra-long-acting biologics with a six-month dosing schedule for patients with severe asthma.
The company could be a key growth driver by the end of this decade. GSK focuses on drug development for respiratory disease. It had previously launched its respiratory syncytial virus (RSV) vaccine, Arexvy.
Tony Wood, the Chief Scientific Officer at GSK, said: "Discovered by our scientists in Stevenage, Depemokimab builds on our deep heritage and leadership in respiratory medicine and has the potential to make a real difference to the millions of people whose lives are affected every day by severe asthma".
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Ab Science révise les calendriers d'essais après trois inspections GCP
Novo Nordisk signe un accord de 2,6 milliards $ avec Hengrui pour un GLP-1 oral
Discussion